Salvage therapies for first relapse of SHH medulloblastoma in early childhood
Neuro-Oncology · 2025
DOI: 10.1093/neuonc/noaf092 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, 2025. Verfasst von Craig Erker und 50 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Department of Paediatrics, IWK Health Centre and Dalhousie University, Halifax, Nova Scotia, Canada. Hauptthemen laut MEDLINE: Medulloblastoma, Salvage Therapy, Neoplasm Recurrence, Local, Cerebellar Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, IWK Health.
Abstract (Originalsprache)
Background
Sonic hedgehog (SHH) medulloblastoma is the most common molecular group of infant and early childhood medulloblastoma (iMB) and has no standard of care at relapse. This work aimed to evaluate the post-relapse survival (PRS) and explore prognostic factors of patients with nodular desmoplastic (ND) and/or SHH iMB.
Methods
This international retrospective study included 147 subjects diagnosed with relapsed ND/SHH iMB between 1995 and 2017, <6 years old at original diagnosis, and treated without initial craniospinal irradiation (CSI). Univariable and multivariable Cox models with propensity score analyses were used to assess PRS for those in the curative intent cohort.
Results
The 3-year PRS was 61.6% (95% confidence interval [CI], 52.2–69.6). The median age at relapse was 3.4 years (interquartile range [IQR], 2.6–4.1). Those with local relapse (40.8%) more often received salvage treatment with surgery (P < .001), low-dose CSI (≤24 Gy; P < .001), or focal radiotherapy (P = .008). Patients not receiving CSI (40.5%) more often received salvage marrow-ablative chemotherapy (HDC + AuHCR [P < .001]). On multivariable analysis, CSI was associated with improved survival (hazard ratio [HR] 0.33 [95% CI, 0.13–0.86], P = .04). Salvage HDC + AuHCR, while clinically important, did not reach statistical significance (HR 0.24 [95% CI, 0.0054–1.025], P = .065).
Conclusions
Survival of patients with relapsed SHH iMB is not satisfactory and relies on treatments associated with toxicities including CSI and/or HDC + AuHCR. Cure at initial diagnosis to avoid relapse is crucial. For patients with localized relapse undergoing resection, alternative salvage regimens that avoid high-dose CSI (>24 Gy) can be considered.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology/Oncology, Department of Paediatrics, IWK Health Centre and Dalhousie University, Halifax, Nova Scotia, Canada.
- Mildred Scheel Cancer Career Center HaTriCS4, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Department of Child and Adolescent Oncology, Gustave Roussy, Paris-Saclay University, Villejuif, France.
- Department of Pediatrics, University of Calgary and Alberta Children's Hospital Research Institute (ACHRI), Calgary, Alberta, Canada.
- Departments of Pediatric Hematology and Oncology, Dell Children's Medical Center of Central Texas and University of Texas, Austin, Texas, USA.
ORCID-Profile: Craig Erker, Martin Mynarek, Kathleen Dorris, Vijay Ramaswamy, Amar Gajjar, Juliette Hukin, Eric Bouffet, Christelle Dufour
Förderung
- NCI NIH HHS
- IWK Health
Zitieren
APA
Erker, C., Mynarek, M., Simbozel, M., Craig, B. T., Harrod, V. L., Cappellano, A. M., Cohen, K. J., Lopez, V. S., Morales La Madrid, A., Cacciotti, C., Baroni, L., Salloum, R., Margol, A. S., Michaiel, G., Aguilera, D., Mazewski, C. M., Kline, C. N., Finlay, J. L., Abdelbaki, M. S., …, & Lafay-Cousin, L. (2025). Salvage therapies for first relapse of SHH medulloblastoma in early childhood. Neuro-Oncology. https://doi.org/10.1093/neuonc/noaf092
Vancouver
Erker C, Mynarek M, Simbozel M, Craig BT, Harrod VL, Cappellano AM, et al. Salvage therapies for first relapse of SHH medulloblastoma in early childhood. Neuro-Oncology. 2025. doi:10.1093/neuonc/noaf092
BibTeX
@article{Erker2025,
author = {Erker, Craig and Mynarek, Martin and Simbozel, Marie and Craig, Brandon T and Harrod, Virginia L and Cappellano, Andrea M and Cohen, Kenneth J and Lopez, Vicente Santa-Maria and Morales La Madrid, Andres and Cacciotti, Chantel and Baroni, Lorena and Salloum, Ralph and Margol, Ashley S and Michaiel, George and Aguilera, Dolly and Mazewski, Claire M and Kline, Cassie N and Finlay, Jonathan L and Abdelbaki, Mohamed S and Murray, Jeffrey C and Dorris, Kathleen and Crooks, Bruce and Ginn, Kevin F and Amayiri, Nisreen and Tippelt, Stephan and Fleischhack, Gudrun and Tonn, Svenja and Gerber, Nicolas U and Lassaletta, Alvaro and Hansford, Jordan R and Khan, Sara and Gilheeney, Stephen W and Hoffman, Lindsey M and Zapotocky, Michal and Larouche, Valérie and Shah, Shafqat and Ramaswamy, Vijay and Gajjar, Amar and Perreault, Sébastien and Mueller, Sabine and Hukin, Juliette and Cheng, Sylvia and Wang, Zhihong J and Matheson, Kara and Bailey, Simon and Bouffet, Eric and Clifford, Steven C and Robinson, Giles and Dufour, Christelle and Rutkowski, Stefan and Lafay-Cousin, Lucie},
title = {Salvage therapies for first relapse of SHH medulloblastoma in early childhood},
journal = {Neuro-Oncology},
year = {2025},
doi = {10.1093/neuonc/noaf092}
}
EUVIMED